Proteome Sciences plc
1.35
GBX
0.00
(0.00%)
ISIN
GB0003104196
Return %
Stock
S&P 500
1Y
-35.49
14.20
3Y
-77.68
81.12
5Y
-73.63
68.34
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Anil Wadhwani
- Full Time Employees
- 32
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Coveham House Cobham SU United Kingdom KT11 3EP
- IPO Date
- Oct 3, 1995
- Website
- proteomics.com
- Similar Companies
- Business
- Proteome Sciences plc (PRM.L) is a specialist provider of contract proteomics services and protein biomarker research and development, utilizing high-sensitivity proprietary mass spectrometry techniques including TMT LC-MS2, TMT LC-MS3, SysQuant, TMTcalibrator, Super-Depletion (top 14 and top 65 proteins), selective reaction monitoring (SRM), parallel reaction monitoring (PRM), TMT SRM, data-independent acquisition (DIA), and single cell proteomics (SCP) for the analysis of tissues, cells, biological fluids, and plasma from human, animal, and plant sources to support drug discovery, development, clinical trials, and biomarker identification, validation, and application; the company also manufactures and exclusively licenses Tandem Mass Tags (TMT) reagents, including TMTpro 11-plex, 18-plex, and 35-plex isobaric tags, to Thermo Fisher Scientific for global distribution in multiplex quantitative proteomics applications. Founded in 1993 and headquartered at Coveham House, Downside Bridge Road, Cobham, Surrey, KT11 3EP, United Kingdom, with laboratory facilities in Frankfurt, Germany, and San Diego, United States, Proteome Sciences operates under ISO 9001:2015 for discovery applications and Good Clinical Laboratory Practice (GCLP) for targeted assays, serving primarily pharmaceutical, biotechnology, and academic customers in the United States, United Kingdom, European Union, and internationally across the life sciences tools and services industry. In recent developments, the company secured a substantial GCLP contract exceeding £500k with a US biopharmaceutical firm in April 2024, followed by a multi-year extension into 2025-2026 as part of a larger clinical study, alongside over £2m in total US orders for 2024; launched first commercial SCP projects in Q4 2024, added label-free DIA services with client projects underway, filed patents for second-generation 6-plex DIA multiplex tags (DXT) with licensing discussions ongoing for 2025, and benefited from strong TMT revenue growth driven by the June 2024 full launch of TMTpro 35-plex; additionally, it obtained a £0.50m loan facility from Vulpes Investment Management in December 2024 and a £1m facility in late 2024 to fund acquisition of a second Exploris mass spectrometer for capacity expansion, while appointing SP Angel Corporate Finance LLP as Nominated Adviser and Broker in November 2025, transitioning Chairman Christopher Pearce to Executive Chairman following CEO Mariola Söhngen's departure in January 2025. The company maintains a portfolio of over 400 patents in proteomics, biomarkers for diseases including cancer, neurodegenerative disorders, and stroke, and proprietary bioinformatics for data insights and analyses.